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Maturity Onset Diabetes of the Young (MODY) is a
monogenic form of diabetes. It consists of a heterogeneous
group of autosomal dominant inherited disorders, with
typical onset in individuals aged less than twenty five
years. There are several different sub-types of MODY
which can be precisely identified using molecular genetic
testing. Modes of presentation vary and can mimic type 1
or 2 diabetes. Making a specific diagnosis of MODY can
have important implications for guidance of appropriate
treatment, prognosis and genetic counselling.
The paediatric diabetes team across the Southern Dis-
trict Health Board provides diabetes care to approximately
160 children and adolescents spread over the largest geo-
graphical region in New Zealand. We present the cases of
three children and their families diagnosed with MODY
over the past two years. This includes two novel muta-
tions, one of which segregates in a unique kindred that is
strongly affected by both MODY and classic autoimmune
mediated diabetes.
These families highlight the features of three of the
more common MODY subtypes; MODY2 - a 13 year
old boy with a novel unclassified variant c.698G>A (p.
Cys233Tyr) in exon 7 of the Glucokinase (GCK) gene,
MODY5 – a 14 year old girl with a novel de novo
dosage change of a 1.3MB deletion in the HNF1b gene,
and MODY3 with a reported nonsense mutation
c.864delGinsCC (p.Gly282ArgfsX25) in exon 4 of the
HNF1a gene observed in an 11 year old girl. In addition
to these index cases, genetic testing has lead to the
diabetes diagnosis of a sibling with a GCK mutation,
and the identification of an HNF1a mutation in another
currently asymptomatic sibling. To date, we have identi-
fied a prevalence of MODY in the paediatric diabetes
population of the lower South Island of approximately
2.5%. This prevalence, along with increasing access to
molecular genetic testing, highlights the importance of
consideration of MODY in atypical diabetes presenta-
tions in the paediatric/adolescent population.
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